$0.84
16.85% today
Nasdaq, Dec 24, 06:19 pm CET
ISIN
US49720K1016
Symbol
HURA

Kintara Therapeutics Inc Stock price

$0.72
-1.17 62.16% 1M
-1.81 71.74% 6M
-3.37 82.52% YTD
-3.43 82.77% 1Y
-147.68 99.52% 3Y
-1,189.28 99.94% 5Y
-34,999.28 100.00% 10Y
-1,548.03 99.95% 20Y
Nasdaq, Closing price Tue, Dec 23 2025
-0.10 12.30%
ISIN
US49720K1016
Symbol
HURA
Industry

Key metrics

Basic
Market capitalization
$43.4m
Enterprise Value
$41.2m
Net debt
positive
Cash
$2.7m
Shares outstanding
51.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
73.1%
Return on Equity
-155.2%
ROCE
-231.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-38.9m | -
EBIT
$-39.1m | $-31.5m
Net Income
$-43.8m | $-32.9m
Free Cash Flow
$-35.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-408.6% | -
EBIT
-407.4% | -78.4%
Net Income
-480.5% | -45.4%
Free Cash Flow
-351.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-0.7
Short interest
5.3%
Employees
-
Rev per Employee
-
Show more

Is Kintara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Kintara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Kintara Therapeutics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Kintara Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Kintara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
73% 73%
-
- Research and Development Expense 28 28
2,500% 2,500%
-
-39 -39
409% 409%
-
- Depreciation and Amortization 0.15 0.15
200% 200%
-
EBIT (Operating Income) EBIT -39 -39
407% 407%
-
Net Profit -44 -44
481% 481%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kintara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kintara Therapeutics Inc Stock News

Neutral
PRNewsWire
9 days ago
Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) Holders TAMPA, Fla. , Dec. 15, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Kintara's REM-001 clinical trial of ten metastatic cutaneous breast...
Neutral
PRNewsWire
13 days ago
Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) targeting completion of enrollment Q4-2026 A mini KOL symposium held on December 5, 2025, provided the scienti...
Neutral
PRNewsWire
15 days ago
TAMPA, Fla. , Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its common stock, Series A warrants to purchase up to ...
More Kintara Therapeutics Inc News

Company Profile

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Head office United States
CEO James Bianco
Founded 2009
Website tuhurabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today